Automate Your Wheel Strategy on DOCS
With Tiblio's Option Bot, you can configure your own wheel strategy including DOCS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DOCS
- Rev/Share 3.1037
- Book/Share 5.4724
- PB 6.3683
- Debt/Equity 0.0103
- CurrentRatio 7.7864
- ROIC 0.1956
- MktCap 6543764392.0
- FreeCF/Share 1.5709
- PFCF 20.8084
- PE 27.572
- Debt/Assets 0.009
- DivYield 0
- ROE 0.239
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | DOCS | Wells Fargo | Equal Weight | Overweight | -- | $55 | Jan. 20, 2026 |
| Initiation | DOCS | RBC Capital Mkts | -- | Outperform | -- | $59 | Jan. 9, 2026 |
| Upgrade | DOCS | Truist | Hold | Buy | -- | -- | Jan. 8, 2026 |
| Upgrade | DOCS | Morgan Stanley | Equal Weight | Overweight | -- | $65 | Dec. 15, 2025 |
| Initiation | DOCS | Barclays | -- | Overweight | -- | $63 | Dec. 9, 2025 |
| Upgrade | DOCS | Raymond James | Outperform | Strong Buy | -- | $65 | Nov. 21, 2025 |
| Initiation | DOCS | BMO Capital Markets | -- | Market Perform | -- | $55 | Nov. 13, 2025 |
| Upgrade | DOCS | BofA Securities | Neutral | Buy | -- | $82 | Oct. 27, 2025 |
| Downgrade | DOCS | JP Morgan | Neutral | Underweight | -- | $62 | Oct. 10, 2025 |
| Downgrade | DOCS | Goldman | Neutral | Sell | -- | $64 | Oct. 1, 2025 |
News
Doximity (DOCS) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Doximity (DOCS) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom?
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Positive
AI momentum is reshaping med-tech, with Tempus AI scaling diagnostics and Doximity leveraging platform-wide AI, strong margins, and cash flow to gain an edge.
Read More
Why Doximity (DOCS) is a Top Growth Stock for the Long-Term
Published: January 28, 2026 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
What Makes Doximity (DOCS) a New Strong Buy Stock
Published: January 27, 2026 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
3 Medical Info Systems Stocks to Gain From Digitization Despite Industry Woes
Published: January 21, 2026 by: Zacks Investment Research
Sentiment: Neutral
Medical Info Systems rides AI and telehealth tailwinds, lifting DOCS, TXG and OMCL, but cyber risks and industry underperformance keep optimism in check.
Read More
Health & Fitness Stocks Positioned for Strong 2026 Growth
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
UNFI, COCO, DOCS and PTON are tapping into the $11T wellness boom with tech, nutrition, and fitness-driven growth.
Read More
Here's Why Doximity (DOCS) is a Strong Growth Stock
Published: January 12, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Doximity (DOCS) Stock Falls Amid Market Uptick: What Investors Need to Know
Published: December 23, 2025 by: Zacks Investment Research
Sentiment: Negative
In the latest trading session, Doximity (DOCS) closed at $43.53, marking a -3.22% move from the previous day.
Read More
Why Doximity (DOCS) is a Top Growth Stock for the Long-Term
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
3 New Year's Resolution Stocks That Could Turn Around in 2026
Published: December 18, 2025 by: MarketBeat
Sentiment: Positive
At the start of the new year, investors seeking a fresh approach might consider stocks that are positioned for a reset. Companies trading at or near their lowest level for 2025 could be primed for gains in the new year if conditions are right.
Read More
Here's Why Doximity (DOCS) is a Strong Growth Stock
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Wall Street is Pounding the Table Over NVDA, CVNA, DOCS
Published: November 21, 2025 by: 24/7 Wall Street
Sentiment: Neutral
CVNA last traded at $313.25 a share after finding support at $285.02, which was double-bottom support dating back to June 2025.
Read More
Why Doximity (DOCS) is a Top Growth Stock for the Long-Term
Published: November 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Doximity Stock Down Despite Q2 Earnings Beat, Revenues Up Y/Y
Published: November 07, 2025 by: Zacks Investment Research
Sentiment: Negative
DOCS Q2 results benefit from the rise in AI-driven engagement. However, the stock plunges nearly 9% in pre-market trading.
Read More
Doximity (DOCS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: October 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Doximity (DOCS) Beat Estimates Again in Its Next Earnings Report?
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Buy These 5 Health and Fitness Stocks for a Stable Portfolio in Q4
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
DOCS, PLNT, UNFI, PTON and PFGC are five health and fitness stocks with growth potential, diversified revenue and resilient demand.
Read More
HIMS vs. DOCS: Which Digital Health Platform Is a Better Investment?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers and Doximity are transforming digital health, but which leads in earnings growth and platform expansion? Let's see.
Read More
DOCS Stock Up in Pre-Market Post Q1 Earnings Beat, Gross Margin Down
Published: August 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity beats first-quarter fiscal 2026 estimates with double-digit revenue growth and lifts its full-year forecast.
Read More
Doximity Analysts Increase Their Forecasts After Strong Q1 Earnings
Published: August 08, 2025 by: Benzinga
Sentiment: Positive
Doximity Inc DOCS reported better-than-expected earnings for the first quarter on Thursday.
Read More
Doximity (DOCS) Reports Next Week: Wall Street Expects Earnings Growth
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
OMCL vs. DOCS: Which Stock Is the Better Value Option?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Doximity (DOCS). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note
Published: July 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the latest trading session, Doximity (DOCS) closed at $59.7, marking a -2.13% move from the previous day.
Read More
Doximity: Slowing Sales And EBITDA Growth
Published: July 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Doximity shares have dropped nearly 25% from February highs, despite strong Q4 earnings and 17% revenue growth year-over-year. Analyst sentiment is mixed, and insider selling has notably increased in 2025. Doximity boasts a robust balance sheet with $915 million in cash, no long-term debt, and an impressive rise in free cash flow in its last reported quarter.
Read More
Doximity (DOCS) Upgraded to Strong Buy: Here's Why
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Doximity (DOCS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Read More
Doximity Crushes The Rule Of 40 - Try Rule Of 58
Published: July 02, 2025 by: Seeking Alpha
Sentiment: Positive
I have a price target of $85 for Doximity by summer 2026. There is lots to be bullish about. Doximity's fundamentals are strong: zero debt, a large cash cushion, and robust free cash flow generation support my bullish outlook. Despite unimpressive 11% revenue growth guidance, DOCS surpasses the Rule of 40 with a Rule of 58, justifying a premium valuation.
Read More
Does DOCS' Shift Toward Enterprise Offerings Signal a Long-Term Pivot?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
DOCS sharpens its enterprise focus with AI and workflow tools, signaling a deeper pivot beyond pharma marketing roots.
Read More
Will AI Tools Like DocsGPT Drive the Next Leg of Growth for DOCS?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
DOCS is leaning on AI tools like Doximity GPT to fuel growth after a strong FY25, but monetization remains early-stage.
Read More
OGN or DOCS: Which Is the Better Value Stock Right Now?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Kuehn Law Encourages Investors of Doximity, Inc. to Contact Law Firm
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Doximity, Inc. (NYSE: DOCS) breached their fiduciary duties to shareholders.
Read More
About Doximity, Inc. (DOCS)
- IPO Date 2021-06-24
- Website https://www.doximity.com
- Industry Medical - Healthcare Information Services
- CEO Jeffrey A. Tangney
- Employees 827